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Abstract. Our understanding of SARS-CoV-2, the virus responsible for coronavirus disease 2019 (COVID-19), its
clinical manifestations, and treatment options continues to evolve at an unparalleled pace. This review sought to sum-
marize the key literature regarding transmission, case definitions, clinical management, and the burden of COVID-19. Our
review of the literature showed that SARS-CoV-2 wasmainly transmitted via inhalation of respiratory droplets containing
the virus and had a mean incubation period of 4–6 days. The commonly reported symptoms were fever (75.3% ± 18.7%)
and cough (62.6% ± 17.7%) across the spectrum of clinical disease—mild, moderate, severe, and critical, but with the
disease phenotype varying with severity. Categorization of these cases for home care or hospital management needs to
be defined, with risk stratification accounting for the age of the patient and the presence of underlying comorbidities. The
case definitions varied among countries, which could have contributed to the differences in the case fatality rates among
affected countries. The severity and risk of deathdue toCOVID-19wasassociatedwith ageandunderlying comorbidities.
Asymptomatic cases, which constitute 40–80% of COVID-19 cases are a considerable threat to control efforts. The
presence of fever and cough may be sufficient to warrant COVID-19 testing, but using these symptoms in isolation will
miss a proportion of cases. A clear definition of aCOVID-19 case is essential for themanagement, treatment, and tracking
of clinical illness, and to inform the quarantine measures and social distancing that can help control the spread of
SARS-CoV-2.
INTRODUCTION
In December 2019, several Health Centers in Wuhan, in the
Hubei Province of China, reported a cluster of patients with
pneumonia of unknown etiology.1,2 Their clinical presenta-
tions were similar to those of SARS outbreak that occurred in
2003.3–5 COVID-19 is the third coronavirus disease to cause
public health outbreaks and has spread more rapidly and
widely than SARS and Middle East respiratory syndrome
(MERS). COVID-19 is now pandemic, with millions of con-
firmed cases and several thousandsof deaths associatedwith
the disease in 210 countries and territories. This review pro-
vides a discussion of the disease transmission, clinical pre-
sentations, variability of case definitions, and review of the
clinical management.
BURDEN AND CASE FATALITY OF COVID-19
Since the first cases were recognized in December 2019,
SARS-CoV-2 has spread around the world, with cases and
fatalities increasing by the thousands daily. While attempting
to define the burden and case fatality of the disease, efforts
have been complicated by different case definitions and
testing procedures, asymptomatic cases that may go un-
recognized and the rapidly evolving nature of the pandemic.
Studies of hospitalized patients have reported fatality rates
ranging from 1.4% to 18.9%, and as high as 61.5% among
those who were critically ill.6–10 Case fatality rates were re-
portedly higher among older adults and the elderly than
among young adults and children. Reported rates include
1.0% among adults aged 50–59 years, 3.5% among 60–69
years, 12.8%among70–79 years, and 20.2%among80 years
or older.11 Among critically ill patients, the case fatality is re-
portedly higher, reaching 50% among adults aged 40–49 years
and 87.5–100% among those older than 70 years.10 The precise
case fatality rate for countries affected by the disease is
unknown—although some models allowing for mild and asymp-
tomatic cases estimated it at 0.51%.12 Despite this uncertainty,
several risk factors for significant outbreaks of severe and fatal
illness have been identified. These include patient characteristics,
disease phenotype, and laboratory biomarkers.6,11,13–16 See
Factors associated with COVID-19 morbidity and mortality for
factors associated with morbidity and mortality.
TRANSMISSION ROUTES OF SARS-COV-2
SARS-CoV-2 is transmitted between humans via respiratory
droplets which are produced when an infected individual talks,
sneezes, or coughs (Figure 1). Droplet transmission can occur
within 1–4 m.17–19 SARS-CoV-2 has been shown to survive in
aerosolized form for more than 3 hours under experimental
conditions, but thismechanical generation of aerosols is unlikely
to mimic the true clinical scenario.20 Certain clinical procedures
involving the upper airway such as obtaining a nose or throat
swab, endotracheal intubation, manual ventilation, or nebuliza-
tion are capable of generating particles < 5 μm, allowing for
airborne transmission in healthcare settings.19 In particular, in-
tensive care units (ICUs) have been associatedwith a higher risk
of infection.17
Fomite transmission, transmission from contact with con-
taminated surfaces, is possible with high rates of contami-
nation of floors and the soles of healthcare staff as well as
computer mice, doorknobs, and trash cans.17 The virus is vi-
able for up to 72 hours on plastic and stainless steel, 24 hours
on cardboard, and 4 hours on copper. These survival times
appear to be longer than those of SARS-CoV-2 under similar
conditions andmaycontribute to thebroader spreadofSARS-
CoV-2 in comparison.20
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Infection from direct contact with body fluids from infected
individuals is likely to be another possible route of trans-
mission. SARS-CoV-2 has been detected in saliva, blood,
urine, tears, feces, and cerebrospinal fluid samples.21–25 Al-
though documented evidence of transmission through these
alternate sources remains unsubstantiated, precautionswhen
handling samples collected from suspected or confirmed
cases is advisable.
The basic reproductive number (R0) of SARS-CoV-2 varies
between populations and depends on demographic and en-
vironmental factors as well as on the control interventions in
place.26 At the onset of the outbreak in Wuhan, before travel
restrictions were introduced, the estimated R0 was 2.35 (95%
CI: 1.15–4.77) but was reportedly reduced to 1.05 (95% CI:
0.41–2.39) a week later.27 Similarly, aboard the Diamond
Princess cruise ship, which carried ∼3,600 people, 712 cases
of COVID-19 and 13 deaths were reported. The R0 was re-
ported as 14.8, before quarantine/isolation precautions were
in place, and was reduced to 1.78 after those measures were
introduced.28 In closed settings, such as nursing facilities,
SARS-CoV-2 may spread rapidly, with one study finding a
64% positivity rate among residents 23 days after the first
positive test.29 Of these patients, 56% tested positive while
still asymptomatic, and it has been hypothesized that asymp-
tomatic individuals contribute significantly to transmission.29
CLINICAL PRESENTATION OF SARS-COV-2 INFECTIONS
The reported incubation period for SARS-CoV-2 has been
variable between studies but has generally ranged between 2
and 11 days, with an average of 4–6 days.30 In one study, the
incubation periodwas estimated at 4.9 days (95%CI: 4.4–5.5)
andwas not significantly different from that of SARS-CoV (4.7,
95% CI: 4.3–5.1) and MERS-CoV (5.8, 95% CI: 5.0–6.5).31
Symptomatic patients with COVID-19 develop a clinical
syndrome similar to that of influenza. Our analysis of 21
studies involving COVID-19 patients showed that the majority
of patients with clinical disease presented fever (75.3%),
cough (62.6%), dyspnea (52.7%), and sore throat (43.9%) as
the commonly reported symptoms (Figure 2). Other reported
symptoms were moderately common (20–38%) and in-
cluded vomiting/nausea, diarrhea, myalgia, fatigue, pharyngeal
FIGURE 1. Identification andmanagement of COVID-19 cases. Monitoring for suspected cases of COVID-19 is crucial to halt the transmission of
SARS-CoV-2. Suspected cases who have had contact with an infected person (asymptomatic/symptomatic) need to be isolated and screened for
SARS-CoV-2 using sensitive nucleic acid amplification tests (NAATs). It is recommended that infected individuals who are asymptomatic self-
isolate and be monitored at home. Individuals who progress to develop clinical disease can be triaged into mild/moderate and severe/critical case
for clinical management/treatment. However, the presence of comorbidities and the age of the patient can be used to triage patients for hospi-
talization or home care. Once recovered, patients should be monitored because they could still be infectious.
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congestion, headache, sputum production, and anorexia
(Figure 2). The less commonly reported symptoms (< 20%)
were abdominal pain, loss of taste/smell, dizziness, and chest
pain (Figure 2).1,32–35 Most of these symptoms appeared within
11 days postinfection, but this may vary depending on age and
comorbidities.6,8,26,36
Chest X-ray (CXR) and computed tomography (CT) features
of disease may appear before COVID-19 disease becomes
symptomatic and have been used to aid in diagnosis. OnCXR,
the most common findings are consolidation and ground-
glass opacities, often with bilateral involvement.37 On CT, the
disease detection rate is high among symptomatic individuals
with a meta-analysis study indicating that ground-glass
opacities are the most common feature, appearing in 83.31%
of cases. This is followed by ground-glass opacities with mixed
consolidation in 58.42%, with other common features including
adjacent pleural thickening, interlobular septal thickening, and air
bronchograms.38
Where illness warrants hospitalization, studies suggest that
this usually occurswithin 5–7daysof symptomonset.26,39 The
average duration of hospital admission ranges from 7 to
17 days and is dependent on disease severity.6,40,41 TheWHO
recommends 2–6 weeks of hospitalization to allow time for
proper treatment and adequate recovery.42 The disease can
progress from mild to critical, with severe respiratory compli-
cations and multiple organ dysfunction, which can be
fatal.1,33,43 In COVID-related deaths, the median time from
symptom onset to death was ∼13–16 days.44,45
Asymptomatic cases. Asymptomatic SARS-CoV-2 infec-
tions, where patients test positive for the virus yet remain
clinically well (Figure 1), constitute a large proportion of
COVID-19 cases. As such, a population screening strategy
based on clinical symptoms alone will miss these cases, in-
creasing transmission risk. Estimates suggest that up to
40–80% of people who test positive for SARS-CoV-2 are
asymptomatic.46,47 In a proportion of individuals who are ini-
tially asymptomatic, a clinical illness will subsequently de-
velop, classifying this group as presymptomatic. A proportion
of these patients may have early identifiable pathology with
studies of clinically well SARS-CoV-2–positive patients find-
ing that 50–67.3% had lung abnormalities on CT at admission
and a proportion of these later developed clinical illness.
Among those without initial CT changes, only 11% later de-
veloped clinical illness.13,48 Presymptomatic cases have also
comprised most of the positive results when testing was
performed in nursing facilities, with these cases likely con-
tributing to transmission.29 Numerous cases of presymptomatic
transmission have been reported, and reports from China
suggest that 12.6% of cases in China were transmitted
asymptomatically.49 These findings raised questions as to
whether most of the patients who were classified as “pre-
symptomatic” (Figure 1) may have had mild symptoms that
went unreported,50–52 and what the extent and transmission
risk is of true asymptomatic cases.
However, there remains a proportion of patients who will be
asymptomatic throughout their illness course. Thedistribution
of asymptomatic cases varies with age, with infected children
more likely to be asymptomatic compared to adults.48,53,54
While the degree of infectivity of asymptomatic patients
compared to those with clinical illness remains uncertain,
there are documented cases of transmission from asymp-
tomatic individuals. These individuals have a median of
9.5 days in which they are able to transmit the virus, and such
transmissions are able to cause severe COVID-19 disease.48,51
AsymptomaticcarrierswithSARS-CoV-2 infectionsposeagreat
threat to COVID-19 control efforts.
Mild illness. Mild COVID-19 illness is defined by un-
complicated symptoms, which can be safely managed in the
FIGURE 2. Commonly reported clinical symptoms of COVID-19. Data were obtained from 21 studies involving COVID-19 patients in-
cluding children and adults. For the pooled analysis, themean percentage of patients who developed a particular symptomwas plotted with
the upper standard error. Fever and cough were the commonly reported symptoms. Data were obtained from published
data.6,10,18,32,34,39,57,59–61,68,69,105,124–129
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outpatient setting (Figure 1). Although theWHOseparates this
category into those with and without mild pneumonia, this
distinction does not influence management and is difficult to
make in patients managed outside of the hospital. For the
purposes of this review, all cases suitable for management in
an outpatient setting will be considered together.
Mild COVID-19 is perhaps less well understood than more
severe disease phenotypes as it is believed that most of such
cases do not present for testing. Based on current data, ap-
proximately 81% of confirmed SARS-CoV-2 infections are
regarded asmild.22 However, it is likely that the number ofmild
cases has been significantly underestimated. During the early
period of the disease outbreak in China, it was estimated that
86% of infections went undocumented because of the fact
that those infected developed non-severe symptoms and,
therefore, did not present for testing.34 The study further es-
timated that undocumented infections were the sources of
infection of 79% of all documented infections.55
Symptoms ofmild COVID-19 are typically those of an upper
respiratory tract infection, with atypical presentations being
more common in elderly and immunosuppressed individu-
als.56 It appears that fever is less characteristic in mild cases.
In patients identified through screening or managed as out-
patients, 40.6–55.9%had fever comparedwith 71.6–98.6%of
hospitalized patients.39,57–60 Headache, pharyngeal conges-
tion, and disorders of taste and smell were reported with
comparative frequency. Malaise, cough, dyspnea, and myal-
gia were less typical than in severe cases.39,57,61–63 Some
authorities are widening case definitions to include symptoms
such as headache, loss of taste or smell, and pharyngeal
congestion as criteria for suspected cases as 59.4% of mild
cases are presenting without fever and 41.6% are presenting
without cough.57,64,65 Although fatalities have been reported
among children, they seem more likely to experience a mild
illness, and the case fatality rate appears significantly lower
than that reported among adults.66 As children can still con-
tribute to transmission, considerations for social distancing
remain relevant despite the generally comparative mild illness
phenotype in this cohort.8
Severe and critical illness. Severe COVID-19 (Figure 1) is
defined by symptoms of significant respiratory distress which
in adults are tachypnea ³ 30 breaths per minute, oxygen
saturation £ 93%, PaO2/FiO2 ratio < 300 mmHg, lung infil-
trates > 50% within 24–48 hours, or clinical assessment of
severe distress.15,56 This definition encompasses acute re-
spiratory distress syndrome (ARDS), defined by acute onset,
PaO2/FiO2 ratio, and bilateral infiltrates onCXR.
67 Through the
course of the illness, most patients will develop a fever
(77–98.6%) and cough (48.2–76%).6,13,22,68 Other common
symptoms include myalgia or fatigue, which appear early in
the illness and are seen in around 18–32.1% of cases,68 sore
throat,69 and dyspnea.22 Fatiguemay ultimately occur in up to
69.6% of patients through the course of the illness, but is
nonspecific.13 SevereCOVID-19 appears to bemore common
in men, with 54.3–68% of hospitalized patients in studies being
males.13,34 It has likewise been associated with comorbidities;
however, severe illnessanddeathcanoccur inpreviouslyyoung,
healthy individuals, including infants.70,71
Complications of severe and critical COVID-19 contribute
significantly to the morbidity and mortality burden. Acute re-
spiratory distress syndrome is well recognized, developing in
19.6%ofhospitalizedpatients amongearly studies inChina.33
Cardiovascular complications are becoming increasingly ap-
parent as more patients reach stages of severe and critical
illness, with cardiomyopathy reported in up to 33%of patients
and arrhythmias in 16.7%.33,72 Other end-organ dysfunction
including acute hepatic and kidney injury is also recognized.72
In addition, severe disease appears to be associated with a
hypercoagulable state with risk of venous thromboembolism
in asmanyas27%of patients andarterial thrombotic events in
3.7%, leading to risk of pulmonary embolism, stroke, myo-
cardial infarction, and systemic arterial embolism.73,74
There is increasing recognition of the existence of central
nervous system (CNS) symptoms in COVID-19 presentations,
as well as neurological complications which increase in fre-
quency with disease severity. In a study of hospitalized pa-
tients, 36.4% had symptoms that were classified as
neurological—dizziness (18.8%), headache (13.1%), impaired
consciousness (7.5%), acute cerebrovascular disease (2.8%),
seizure (0.5%), and ataxia (0.5%).75 These were in addition to
symptoms relating to peripheral nervous and sensory func-
tion.75 Central nervous system symptoms were associated
with laboratory risk factors for severe disease including lym-
phocytopenia; 45.5% of severe infections had nervous sys-
tem manifestations.75 Furthermore, there have been reported
cases of COVID-19–associated stroke, encephalitis, acute
transverse myelitis, perfusion abnormalities on CT, and
Guillain–Barre syndrome.74,76–81 These included large-vessel
strokes in five patients (younger than 50 years) in New York
City, United States.74 These observations raise concerns
about possible neurological effects of the virus, the mecha-
nisms of which are still a cause for speculation.82
Critical cases of COVID-19 are defined by respiratory failure
requiring mechanical ventilation, and septic shock or organ
dysfunction necessitating intensive care.15 Critical COVID-19
cases were recorded in 5–6% of SARS-CoV-2 infections
during the epidemic phase in China.15,71 In other studies of
hospitalized patients, the proportion of COVID-19 cases re-
quiring ICU admission ranged from 5% to 40.7%.6,9,22,39,83 A
need for invasive mechanical ventilation has been reported
in 2.3–12.3% of hospitalized patients,6,39,60 whereas the re-
quirement for extracorporeal membranous oxygenation (ECMO)
occurred in 0.5–3%of patients.6,34 Critical COVID-19 has a case
fatality rate of 49.0% recorded among thosewith critical disease
in China, and early studies from the United States suggest it is
likely to be similarly high.71,84
Recovery from COVID-19. Once patients recover from
COVID-19 (Figure 1), they may remain contagious, as evi-
denced by case reports of positive reverse transcriptase-
polymearse chain reaction (RT-PCR) throat swabs 5–13 days
after symptom resolution. This is even present in recovered pa-
tientswhohave registeredapreviousswab-negativeRT-PCRfor
SARS-CoV-2.85 Viral shedding has been observed for up to
37 days in survivors with amedian duration of 20 days.43 SARS-
CoV-2 has also been detected in fecal specimens 18–30 days
after illness onset in children,69 suggesting that prolonged
shedding may still be possible during and after recovery.
Studies of vertical transmission of SARS-CoV-2 remain lim-
ited; the low numbers of documented probable cases suggest it
is a rare phenomenon where it occurs.86–89 Although SARS-
CoV-2–specific IgM has been detected in infant sera of COVID-
19–positivemothers, it is asyetuncertainwhether this represents
passive immunization, such as through an altered placenta, or
disease transmission with infant immune response.90
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Immunity and reinfection with SARS-CoV-2. Our un-
derstanding of the immune responses against SARS-CoV-2
infections is still unfolding as more patient data are analyzed.
Seroconversion in infected individuals was observed 1–2
weeks post-symptom onset.91 Studies of immune responses
in SARS-CoV-2–infected patients have shown increased
presence of follicular helper T cells, and activated CD4+ and
CD8+ T cells with the detection of immunoglobulin A, IgM, and
IgG against the SARS-CoV-2 spike, nucleocapsid, and en-
velop proteins.23,92–95 There are suggestions that polyclonal
antibodies against SARS-CoV-2may be used as therapeutics
for COVID-19 patients; others have suggested convalescent
plasma as a source of these antibodies.96–98 Data on the
breadth, strength, and longevity of these immune responses
to protect against disease and reinfection are limited and re-
main a field to be explored.99 However, there seems to be a
general lack of long-lived antibody responses against COVID-
19 in general.
There is no reliable evidence to suggest that COVID-19
patients who have recovered from the disease can be rein-
fected. Available data from reinfection studies in monkeys
(rhesus macaques) showed that prior infection with SARS-
CoV-2 conferred protection against reinfection with the same
strain of the virus.100 This suggests that immune response to
SARS-CoV-2 could protect against reinfection.101 Case re-
ports of SARS-CoV-2 PCR-positive results in individuals who
were previously PCR negative have not been thoroughly in-
vestigated nor confirmed. Others have suggested that this
could be because of re-detection of existing infections, which
were circulating at low densities.102 Thus, detection of the
virus following recovery needs to be interpreted with caution
as it is more likely to be shedding of the virus from a resolving
infection.
COVID-19 CASE DEFINITIONS
Defining the scope of the COVID-19 pandemic has been
challenging because of the need to refine case definitions as
the pandemic progressed and as clinical presentations be-
come more clearly understood. These case definitions have
been used to determine whom to test and to guide case in-
vestigations of possible contacts. By influencing testing al-
gorithms, they have greatly impacted the confirmed test
outcomes. As an example, case definitions in China were
changed on February 12, 2020, to include clinically diagnosed
mild cases, resulting in an increase of > 15,000 cases in a
single day.7 Thus, developing consistent case definitions,
whenever possible, is necessary to track metrics of the dis-
ease and its spread.
COVID-19 case definitions have been developed and
modified in different jurisdictions according to local circum-
stances and authorities (Table 1). In Canada, the definition of a
probable case has beenwidened to require only one symptom
of illness in addition to an epidemiological risk factor; the
breadth of symptoms required for a suspected case was later
increased to include general flu-like symptoms, including
headache and sore throat.65 In Australia, where case defini-
tions are used to determine testing priorities, additional efforts
have been devoted to defining high-risk settings such as
residential facilities and the nature of a close contact as it
relates to in-person interactions andproximity (Table 1). These
definitions are highly significant as they determine who
receives testing andwhich patients need to be regarded as at-
risk for transmitting the virus. These precautions require
resources—including equipment and personnel—such that
case definitions must balance capturing possible COVID-19
infections against burdening the healthcare system with in-
dividuals with a low probability of infection.
FACTORS ASSOCIATED WITH COVID-19 MORBIDITY
AND MORTALITY
The risk of severe or fatal COVID-19 has been associated
with three key categories of risk factors: patient characteris-
tics, disease characteristics, and biomarkers.
Patient characteristics. Age has consistently been asso-
ciated with risk of COVID-19 disease. Among COVID-19 pa-
tients, older adults and the elderly compared with young
adults and children have had an increased likelihood of severe
disease, increased risk of mortality, higher admission rates,
and increased length of hospital stay.9,11,16,41,43,60,103,104
COVID-19 mortality and morbidity have further been asso-
ciated with comorbidities (Table 2), which may vary between
countries.6,68 In the general population, the mortality rate
(2.3%) due to COVID-19 was reportedly lower than among
patients with chronic disease, increasing to 10.5% in patients
with cardiovascular disease, 7.3% among patients with di-
abetes mellitus, 6.3% among those with chronic respiratory
diseases, 6% among patients with hypertension, and 5.6% in
cancer patients.71 Such diseases also increase the risk of re-
quiring invasive ventilation, with this reported at increased
rates among patients with obesity, diabetes, hypertension,
chronic pulmonary disease, cardiovascular disease, and
cancer.16,41,105,106 In the United States, underlying health
conditions and risk factors were identified in 27% of non-
hospitalized, 71% of hospitalized, and 78% ICU cases due to
COVID-19.107 In one Italian study, 99.2% of COVID-19 cases
admitted to the hospital had underlying chronic diseases, and
in China, chronic illness was identified in 40% of cases of
critical illness.10,11
Other risk factors including gender, host genetics, and
country of residence have been reported. Most of the patients
with severe and fatal disease across multiple settings have
beenmale, although the reasons for this remain unclear.41,45,60
In addition, factors including ethnicity, health insurance status,
and country of residence have been implicated as possible
risk factors for disease outcome.108 Host genetics including
polymorphisms in the human receptor, angiotensin-converting
enzyme-2, for SARS-CoV-2, may play a role in infection and
severity of COVID-19.109–111
Disease characteristics. Several disease characteristics
at presentation have additionally been identified asmarkers of
progression from mild/moderate to severe disease. These
have been previously outlined in terms of disease phenotype
for mild versus severe/critical disease. They include fever,
dyspnea, tachypnea, and chest tightness.41,45,105 Higher Se-
quential Organ Failure Assessment (SOFA) scores have been
associated with increased mortality risk and may be a tool for
assessing mortality risk at admission.10,43
Biomarkers. Biomarkers including neutrophilia, lympho-
cytopenia, and elevated creatinine, bilirubin, aspartate ami-
notransferase, troponin, D-dimer, interleukin 6, ferritin,
C-reactive protein, lactate dehydrogenase, blood urea ni-
trogen, creatinine kinase, and procalcitonin have been
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associated with severe disease and mortality due to COVID-
19.10,41,43,45,75,104,105,112
MANAGEMENT OF COVID-19 CASES
For most patients, COVID-19 presents as a mild illness that
can be managed at home with rest and simple analgesics/
antipyretics for symptom relief (Figure 1). Paracetamol has
been suggested as the drug of choice for symptom relief,
whereas anecdotal evidence of non-steroidal anti-inflammatory
drug (NSAID)-associated harm in COVID-19–infected patients is
being investigated.113
To not overburden health staff, most healthcare facilities
manage milder cases of COVID-19 on an outpatient basis,
with patients self-isolating in their own homes. As yet, the
benefits of early interventions that havebeenproposed—such
as oxygen therapy—remain unclear.114 The rapidly rising case
numbers in many countries continue to impose a significant
burden on the healthcare system, making inpatient manage-
ment of mild cases challenging.
Once patients are admitted to hospital, treatments fall into
three key categories: supportive care, treatment of coinfection
and comorbidity, and disease-modifying treatments, which
currently remain experimental.
For patients with severe or critical SARS-CoV-2, supportive
care is the current mainstay of treatment (Figure 1). This in-
cludes attention to fluids and electrolytes, monitoring for
complications, facilitating symptomatic management, and
providing respiratory support. Respiratory support can be
provided in a stepwise fashion as required, moving from ox-
ygen therapy through to noninvasive ventilation, and then
intubation and mechanical ventilation. In ARDS, there is evi-
dence that prone positioning of patients may improve oxy-
genation, and it is currently being recommended for
hospitalized COVID-19 patients.64,66,115 With a high fatality
rate observed in mechanically ventilated patients and pan-
demic cases placing enormous strain on global ventilator
supply, it is of note that isolated hypoxemia can be well tol-
eratedwhere respiratory effort remains in an acceptable range
and is not necessarily an appropriate trigger for intubation.115
Where intubation and mechanical ventilation is required, it
should be tailored to the disease phenotype and aim to pre-
vent further lung injury.115 Extracorporeal membranous oxy-
genation may be used if available for refractory hypoxia. It is
important to note that although respiratory support measures
are integral to COVID-19 management, they also create high-
risk environments in which airborne transmission of the virus
may be possible.19 These measures include intubation, neb-
ulized treatments, moving patients to a prone position, and
positive-pressure noninvasive ventilation. During these ac-
tivities, it important that healthcare personnel wear appropri-
ate personal protective equipment including N95 mask and
eye protection (Figure 1).
Where COVID-19 is causing severe illness or sepsis, the
WHO recommends empirical antimicrobial treatment, with
other sources suggesting this be considered in any severe
infection.66 In addition, consideration may be given to a
neuraminidase inhibitor in the event of coinfection with in-
fluenza. Coinfection of COVID-19 patients with other patho-
gens including influenza A and B, respiratory syncytial virus,
rhinovirus, and adenovirusmaybe common, occurring in 22%
of cases in some reports.116 However, this depends on region
and season. Coinfection with other respiratory pathogens
may increase COVID-19 severity. As such, severe disease
warrants testing and treatment for these coinfections.
Disease-modifying treatments for COVID-19 remain under
investigation (Supplemental Tables 1 and 2). Of note in this
category, preliminary results from the Recovery trial indicate
that low-dose dexamethasone reduces mortality among
COVID-19 patients requiring respiratory support, by up to
one-third in those requiring ventilation.117 As such, and with
no significant harms associated with the medication in this
trial, dexamethasone is now being recommended for con-
sideration in severe disease.118 In addition, there is ongoing
interest in remdesivir, an antiviral previously trialed in Ebola
virus disease. Whereas early trials were equivocal regarding
possible benefit,119 recent preliminary results from a ran-
domized controlled trial suggest remdesivir may improve re-
covery time and rate from COVID-19.120 There are numerous
other drugs under ongoing investigation because of their
potential to modify some aspect of the COVID-19 disease
course (Supplemental Table 1); these have been reviewed
elsewhere and remain an area of active research.121,122
Meanwhile, there is extensive ongoing research into potential
candidate vaccines (Supplemental Table 2), with 13 in clinical
evaluation and hundreds more being studied. Candidates in-
clude RNA, DNA, protein subunit, nonreplicating viral vector,
and inactivated platforms. These additions will continue to
be of great significance as control efforts continue.123 See
Supplemental Table 1 for drugs and Supplemental Table 2 for
vaccines and immunotherapies in development for COVID-19.
CONCLUSION
SARS-CoV-2, the causative agent of the novel coronavirus
disease, COVID-19, has caused a huge disease burden
globally in the short time it has been recorded. A clear de-
scriptionof symptomsassociatedwith thedisease is crucial to
establish the case definition for clinical management and for
epidemiological purposes. Most of the patients are likely to
remain asymptomatic or mildly symptomatic. Those that do
develop clinical disease will most typically have fever and
cough, but these remain absent in up to 59.4% and 41.6% of
cases, respectively, creating challenges for disease detection
and control. The presence of either of these symptoms should
be a basis for suspecting a SARS-CoV-2 infection. However,
because other respiratory viruses present with similar symp-
toms, a laboratory test specific to SARS-CoV-2 should be
performed.
Nearly every country in the world has been affected by
COVID-19. It is important to note that the definitions for
COVID-19 cases vary between countries and territories af-
fected by the disease, and this in turn may have affected the
public health response. When defining cases, it is important
that national guidelines account for the age distribution of the
population and the presence of comorbidities including car-
diovascular diseases, diabetes, and cancer, which increase
the risk of developing severe and/or critical disease, and in-
crease the risk of fatality. Where transmission is still in the
exponential phase of SARS-CoV-2 infections, it is critical that
clinical cases are triaged to prioritize management and treat-
ment without overwhelming the healthcare system.
Although several drugs are beginning to show promise in
clinical trials, it may take months before these become
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sufficiently studied and available for widespread clinical use.
Hence, it is important that quarantine and isolation measures
are strictly enforced to control the disease outbreak. A major
challenge, however, to controlling SARS-CoV-2 transmission
is how to identify the “silent spreaders”whoare asymptomatic
carriers of the infection.
Limitations of the study.During the reviewperiod, the data
on COVID-19 constantly changed with increasing amounts of
literature, both peer-reviewed and non–peer-reviewed. COVID-
19 data were dependent on country-level definitions and testing
rates.
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